Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Spectrum Pharmaceuticals Inc Issues FY 2012 Revenue Guidance Above Analysts' Estimates-Conference Call
Spectrum Pharmaceuticals Inc announced that it expects pro-forma revenue to exceed $300 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $270 million for fiscal 2012.
Latest Developments for Spectrum Pharmaceuticals Inc
- Spectrum Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
- Spectrum Pharmaceuticals Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates
- Spectrum Pharmaceuticals Inc Comments On FY 2013 Guidance
- Spectrum Pharmaceuticals Inc Announces Positive RenaZorb Phase 1 Clinical Data
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters